Major Milestone For SK Biopharm As Anti-Epileptic Gets US Approval

SK Biopharmaceuticals receives US approval for novel anti-epileptic drug, marking a major milestone for the South Korean firm in its goal of becoming a fully integrated global pharma and potentially boosting its huge planned IPO. Through its US subsidiary, the SK Group company will independently market and sell the product in the world’s biggest single market.

MRI
SK's New Treatment Option For Refractory Epilepsy To Launch In 2020 • Source: Shutterstock

SK Biopharmaceuticals Co. Ltd. has received US FDA approval for its novel anti-epileptic drug Xcopri (cenobamate), for the treatment of partial onset seizures in adults, providing a new treatment option for refractory epileptic patients.

A new effective therapy for drug-resistant epilepsy has been seen as one of the most pressing unmet needs in this sector

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip